Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

News & Events

Point-of-care Strep A tests set to save lives in remote settings

Instant diagnosis and treatment of potentially life-threatening Strep A infections is now very close to reality across Australia’s remote and regional areas thanks to molecular point-of-care testing (POCT) that slashes result times from five days to just minutes.

News & Events

Australia a key contributor to global commitment to end deadly rheumatic heart disease

The World Health Organisation resolution for global action to tackle rheumatic heart disease (RHD) will have significant implications for Australia, which has some of the highest rates of the disease in the world.

Research

Strep A: challenges, opportunities, vaccine-based solutions and economics

Streptococcus pyogenes (Strep A) is a leading cause of morbidity and mortality across the globe, annually causing hundreds of millions of cases of disease.

Research

Rheumatic Heart Disease

Rheumatic heart disease (RHD) is the most important cause of acquired cardiovascular disease in children and young adults. Virtually non-existent in most of Australia, it still predominantly affects Aboriginal communities.

Research

Rheumatic heart disease: infectious disease origin, chronic care approach.

Rheumatic heart disease (RHD) is a chronic cardiac condition with an infectious aetiology, causing high disease burden in low-income settings.

Research

Primary prevention of rheumatic fever in the 21st century: evaluation of a national programme

Population-based primary prevention of ARF through sore throat management may be effective in well-resourced settings like New Zealand

Research

Standardizing clinical care measures of rheumatic heart disease in pregnancy: A qualitative synthesis

Pregnancy provides an opportunity to strengthen health system responses and address whole-of-life health for women with rheumatic heart disease

Research

The economic and health burdens of diseases caused by group A Streptococcus in New Zealand

In preparation for the future arrival of a group A Streptococcus (GAS) vaccine, this study estimated the economic and health burdens of GAS diseases in New Zealand. The annual incidence of GAS diseases was based on extrapolation of the average number of primary healthcare episodes managed each year in general practices (2014-2016) and on the average number of hospitalizations occurring each year (2005-2014). Disease incidence was multiplied by the average cost of diagnosing and managing an episode of disease at each level of care to estimate the annual economic burden.

Research

Echocardiographic screening in a resource poor setting: Borderline rheumatic heart disease could be a normal variant

Cross-sectional observational study across ten primary schools in Fiji in school children aged 5-14 years.